{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:37:41Z","timestamp":1792607861546,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lfs.2020.117996","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T07:04:31Z","timestamp":1592895871000},"page":"117996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":229,"special_numbering":"C","title":["Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions"],"prefix":"10.1016","volume":"256","author":[{"given":"A.A.D.T.","family":"Abeysinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.U.S.","family":"Deshapriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Udawatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.117996_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2004.05.005","article-title":"Dementia of Alzheimer\u2019s disease and other neurodegenerative disorders - Memantine, a new hope","volume":"51","author":"Sonkusare","year":"2005","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","article-title":"Update on Alzheimer\u2019s disease therapy and prevention strategies","volume":"68","author":"Graham","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.lfs.2020.117996_bb0015","series-title":"2018 Alzheimer\u2019s Disease Facts and Figures","author":"Alzheimer\u2019\u2019s Association","year":"2018"},{"key":"10.1016\/j.lfs.2020.117996_bb0020","series-title":"Ganong\u2019s Review of Medical Physiology","author":"Barret","year":"2012"},{"key":"10.1016\/j.lfs.2020.117996_bb0025","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.neuropsychologia.2008.07.010","article-title":"Brain substrates of implicit and explicit memory: the importance of concurrently acquired neural signals of both memory types","volume":"46","author":"Voss","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.lfs.2020.117996_bb0030","first-page":"15","article-title":"The cognitive neuroscience of working memory","volume":"66","author":"D\u2019Esposito","year":"2015","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.lfs.2020.117996_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0361-9230(99)00094-5","article-title":"The early history of the synapse: from Plato to Sherrington","volume":"50","author":"Bennett","year":"1999","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.lfs.2020.117996_bb0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/gps.3766","article-title":"Semantic memory and language dysfunction in early Alzheimer\u2019s disease: a review","volume":"27","author":"Verma","year":"2012","journal-title":"Int. J. Geriatr. Psychiatry."},{"key":"10.1016\/j.lfs.2020.117996_bb0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.31887\/DCNS.2013.15.4\/hjahn","article-title":"Memory loss in Alzheimer\u2019s disease","volume":"15","author":"Jahn","year":"2013","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.lfs.2020.117996_bb0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1476-5381.1971.tb07066.x","article-title":"Role of transmitter uptake mechanisms in synaptic neurotransmission","volume":"41","author":"Iversen","year":"1971","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117996_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cobeha.2020.01.013","article-title":"Acetylcholine and the complex interdependence of memory and attention","volume":"32","author":"Decker","year":"2020","journal-title":"Curr. Opin. Behav. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2020.117996_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/chemosensors6010001","article-title":"Recent advances in the detection of neurotransmitters","volume":"6","author":"Si","year":"2018","journal-title":"Chemosensors"},{"key":"10.1016\/j.lfs.2020.117996_bb0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11033-010-0128-9","article-title":"Glutamate receptors and signal transduction in learning and memory","volume":"38","author":"Peng","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.lfs.2020.117996_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-190577","article-title":"Neurotransmitter imbalance in the brain and Alzheimer\u2019s disease pathology","volume":"72","author":"Snowden","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/acs.biochem.9b00775","article-title":"Synaptic copper, amyloid-\u03b2, and neurotransmitters in Alzheimer\u2019s disease","volume":"59","author":"Nam","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2020.117996_bb0080","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/ggi.13488","article-title":"Dementia and Alzheimer\u2019s disease risks in patients with autoimmune disorders","volume":"18","author":"Li","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.lfs.2020.117996_bb0085","article-title":"Age-specific epigenetic drift in late-onset Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117996_bb0090","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410330306","article-title":"Risk factors for late-onset Alzheimer\u2019s disease: a population-based, case-control study","volume":"33","author":"Fratiglioni","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.lfs.2020.117996_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuro.2017.03.006","article-title":"Risk factors associated with the onset and progression of Alzheimer\u2019s disease: a systematic review of the evidence","volume":"61","author":"Hersi","year":"2017","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.lfs.2020.117996_bb0100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuroscience.2005.06.017","article-title":"Estrogen-containing hormone therapy and Alzheimer\u2019s disease risk: understanding discrepant inferences from observational and experimental research","volume":"138","author":"Henderson","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2020.117996_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0306-4522(95)00331-C","article-title":"Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer\u2019s Disease","volume":"69","author":"Nagy","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2020.117996_bb0110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3233\/JAD-2010-1337","article-title":"Early-versus late-onset Alzheimer\u2019s disease: more than age alone","volume":"19","author":"Koedam","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0115","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/207178","article-title":"Alzheimer\u2019s disease clinical and research update for health care practitioners","volume":"2013","author":"Defina","year":"2013","journal-title":"J. Aging Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/joim.12178","article-title":"Advances in the prevention of Alzheimer\u2019s disease and dementia","volume":"275","author":"Solomon","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.lfs.2020.117996_bb0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1042\/BST0350416","article-title":"The APP family of proteins: similarities and differences","volume":"35","author":"Walsh","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.lfs.2020.117996_bb0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from Alzheimer\u2019s disease","volume":"430","author":"Mattson","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.117996_bb0135","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.lfs.2020.117996_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(92)90003-K","article-title":"Synaptic pathology in Alzheimer\u2019s disease: immunological data for markers of synaptic and large dense-core vesicles","volume":"46","author":"Lassmann","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2020.117996_bb0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Gody\u0144","year":"2016","journal-title":"Pharmacol. Reports."},{"key":"10.1016\/j.lfs.2020.117996_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"A review on Alzheimer\u2019s disease pathophysiology and its management: an update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Reports."},{"key":"10.1016\/j.lfs.2020.117996_bb0155","series-title":"Sequential Proteolysis by \u03b3-Secretase and Its Implications for Alzheimer\u2019s Disease","first-page":"1","author":"Fernandez","year":"2015"},{"key":"10.1016\/j.lfs.2020.117996_bb0160","doi-asserted-by":"crossref","first-page":"21326","DOI":"10.1074\/jbc.M112.356659","article-title":"Generation of Alzheimer disease-associated amyloid \u03b2 42\/43 peptide by \u03b3-secretase can be inhibited directly by modulation of membrane thickness","volume":"287","author":"Winkler","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.117996_bb0165","first-page":"1","article-title":"\u03b2-Amyloid degradation and Alzheimer\u2019s disease","volume":"2006","author":"Wang","year":"2006","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.lfs.2020.117996_bb0170","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/acel.12054","article-title":"Ca2+-dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid \u03b2-treated astrocytes and in a model of Alzheimer\u2019s disease","volume":"12","author":"Alberdi","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.lfs.2020.117996_bb0175","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ejmech.2016.07.054","article-title":"Protein aggregation and neurodegenerative diseases: from theory to therapy","volume":"124","author":"Kumar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117996_bb0180","first-page":"1","article-title":"The efficacy and pharmacological mechanism of Zn7MT3 to protect against Alzheimer\u2019s disease","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.117996_bb0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/1568007054546117","article-title":"Alzheimer\u2019s disease-associated neurotoxic mechanisms and neuroprotective strategies","volume":"4","author":"Pereira","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.lfs.2020.117996_bb0190","article-title":"Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration","volume":"33","author":"Wang","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0195","author":"Prince"},{"key":"10.1016\/j.lfs.2020.117996_bb0200","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2105\/AJPH.84.8.1261","article-title":"The US economic and social costs of Alzheimer\u2019s disease revisited","volume":"84","author":"Ernst","year":"1994","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.lfs.2020.117996_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: the path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0210","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1533317509340025","article-title":"The caregiver\u2019s burden of Alzheimer patients: differences between live-in and non-live-in","volume":"24","author":"Raccichini","year":"2009","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"key":"10.1016\/j.lfs.2020.117996_bb0215","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JAD-170518","article-title":"Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer\u2019s disease","volume":"61","author":"Black","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0220","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/BF00930895","article-title":"Upsetting social interactions and distress among Alzheimer\u2019s disease family care-givers: a replication and extension","volume":"16","author":"Kiecolt-Glaser","year":"1988","journal-title":"Am. J. Community Psychol."},{"key":"10.1016\/j.lfs.2020.117996_bb0225","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"308","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117996_bb0230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0166-2236(81)90090-4","article-title":"Acetylcholine, aging and Alzheimer\u2019s disease. Implications for treatment","volume":"4","author":"Corkin","year":"1981","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.lfs.2020.117996_bb0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuropharm.2010.02.010","article-title":"Neurochemical basis for symptomatic treatment of Alzheimer\u2019s disease","volume":"59","author":"Francis","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2020.117996_bb0240","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1471-4159.2006.04211.x","article-title":"Disease modifying therapy for AD?","volume":"99","author":"Golde","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2020.117996_bb0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrd2314","article-title":"Therapies for Alzheimer\u2019s disease","volume":"6","author":"Melnikova","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117996_bb0250","series-title":"FDA Approves New Drug to Treat Dementia","author":"Actavis","year":"2015"},{"key":"10.1016\/j.lfs.2020.117996_bb0255","series-title":"Drug Des. Discov. Alzheimer\u2019s Dis.","first-page":"426","article-title":"Research strategies developed for the treatment of Alzheimer\u2019s disease. Reversible and pseudo-irreversible inhibitors of acetylcholinesterase: Structure-activity relationships and drug design","author":"Alcolea-Palafox","year":"2014"},{"key":"10.1016\/j.lfs.2020.117996_bb0260","article-title":"New acetylcholinesterase inhibitors for Alzheimer\u2019s disease","volume":"2012","author":"Mehta","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/14737175.1.1.61","article-title":"Use of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"1","author":"Moghul","year":"2001","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.lfs.2020.117996_bb0270","first-page":"1","article-title":"The role of NMDA receptors in Alzheimer\u2019s disease","volume":"13","author":"Liu","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.lfs.2020.117996_bb0275","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2016.04.013","article-title":"Recent progress in multifunctional metal chelators as potential drugs for Alzheimer\u2019s disease","volume":"327\u2013328","author":"Santos","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.lfs.2020.117996_bb0280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3163\/1536-5050.100.1.018","article-title":"Martindale: the complete drug reference. 37th ed","volume":"100","author":"Wisher","year":"2012","journal-title":"J. Med. Libr. Assoc."},{"key":"10.1016\/j.lfs.2020.117996_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5664\/jcsm.26438","article-title":"Donepezil in the treatment of narcolepsy","volume":"2","author":"Niederhofer","year":"2006","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.lfs.2020.117996_bb0290","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7609.1000123","article-title":"Absorption, distribution and excretion pattern of oral and transdermal donepezil hydrochloride after single and repeated administration to the rat","volume":"3","author":"R","year":"2012","journal-title":"J. Drug Metab. Toxicol."},{"key":"10.1016\/j.lfs.2020.117996_bb0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.8.1.9","article-title":"Galantamine in Alzheimer\u2019s disease","volume":"8","author":"Razay","year":"2008","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.lfs.2020.117996_bb0300","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs."},{"key":"10.1016\/j.lfs.2020.117996_bb0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488410791110805","article-title":"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer s disease, in healthy subjects and patients","volume":"5","author":"Huang","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117996_bb0310","first-page":"1","article-title":"Rivastigmine for Alzheimer\u2019s disease","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2020.117996_bb0315","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0149-2918(98)80127-6","article-title":"Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease","volume":"20","author":"Polinsky","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0320","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/14740330802528420","article-title":"Memantine: a comprehensive review of safety and efficacy","volume":"8","author":"Kavirajan","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.lfs.2020.117996_bb0325","author":"FDA approved drug Products"},{"key":"10.1016\/j.lfs.2020.117996_bb0330","series-title":"British National Formulary 78","author":"Joint Formulary Committee","year":"2019"},{"key":"10.1016\/j.lfs.2020.117996_bb0335","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2165\/00002512-200724110-00001","article-title":"Is long-term treatment of Alzheimer\u2019s disease with cholinesterase inhibitor therapy justified?","volume":"24","author":"Seltzer","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.lfs.2020.117996_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001190.pub3","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2020.117996_bb0345","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD 2000): randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117996_bb0350","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1185\/030079904X12555","article-title":"Effects of galantamine in patients with mild Alzheimer\u2019s disease","volume":"20","author":"Orgogozo","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lfs.2020.117996_bb0355","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(03)00486-1","article-title":"Memantine for the treatment of dementia","volume":"2","author":"Wilcock","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2020.117996_bb0360","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00019053-200321050-00004","article-title":"Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer\u2019s disease","volume":"21","author":"Wimo","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.lfs.2020.117996_bb0365","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2147\/DDDT.S86463","article-title":"A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease","volume":"10","author":"Deardorff","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0370","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/14656566.2018.1519022","article-title":"An evaluation of memantine ER + donepezil for the treatment of Alzheimer\u2019s disease","volume":"19","author":"Calhoun","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.lfs.2020.117996_bb0390","series-title":"Prescr. Inf.","first-page":"1","article-title":"FDA approved drug products, Namenda\u00ae, prescribing information","year":"2003"},{"key":"10.1016\/j.lfs.2020.117996_bb0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1471-4914(03)00022-4","article-title":"Immunotherapy for Alzheimer\u2019s disease: will vaccination work?","volume":"9","author":"Dodart","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lfs.2020.117996_bb0400","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1620\/tjem.220.95","article-title":"Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies","volume":"220","author":"Tabira","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.lfs.2020.117996_bb0405","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lfs.2020.117996_bb0410","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1286-4579(00)00355-5","article-title":"Preventing infectious disease with passive immunization","volume":"2","author":"Zeitlin","year":"2000","journal-title":"Microbes Infect."},{"key":"10.1016\/j.lfs.2020.117996_bb0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.autrev.2005.06.007","article-title":"Immunotherapy of Alzheimer\u2019s disease (AD): from murine models to anti-amyloid beta (A\u03b2) human monoclonal antibodies","volume":"5","author":"Geylis","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.lfs.2020.117996_bb0420","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/acn3.761","article-title":"Immunotherapy with ponezumab for probable cerebral amyloid angiopathy","volume":"6","author":"Leurent","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.lfs.2020.117996_bb0425","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2174\/092986706777452489","article-title":"Development of BACE1 inhibitors for Alzheimers disease","volume":"13","author":"Guo","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117996_bb0430","first-page":"1","article-title":"BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease, Alzheimer\u2019s","volume":"6","author":"Vassar","year":"2014","journal-title":"Res. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2018.00178","article-title":"Highlights in BACE1 inhibitors for Alzheimer\u2019s disease treatment","volume":"6","author":"Coimbra","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.lfs.2020.117996_bb0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1039\/C0NP00027B","article-title":"Natural products as a source of Alzheimer\u2019s drug leads","volume":"28","author":"Williams","year":"2011","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.lfs.2020.117996_bb0445","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1073\/pnas.0408007101","article-title":"Processing of Notch and amyloid precursor protein by \u03b3-secretase is spatially distinct","volume":"101","author":"Tarassishin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.117996_bb0450","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrn785","article-title":"\u03b3-Secretase, notch, A\u03b2 and Alzheimer\u2019s disease: where do the presenilins fit in?","volume":"3","author":"Sisodia","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.lfs.2020.117996_bb0455","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00023210-200620050-00002","article-title":"Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer\u2019s disease","volume":"20","author":"Evin","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lfs.2020.117996_bb0460","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1745-7254.2008.00752.x","article-title":"Multipotent natural agents to combat Alzheimer\u2019s disease. Functional spectrum and structural features","author":"Ji","year":"2008","journal-title":"Acta Pharmacol. Sin. Feb"},{"key":"10.1016\/j.lfs.2020.117996_bb0465","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/ern.12.43","article-title":"New and emerging treatments for Alzheimers disease","volume":"12","author":"Corbett","year":"2012","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.lfs.2020.117996_bb0470","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer\u2019s disease: focus on disease modifying drugs","volume":"73","author":"Salomone","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117996_bb0475","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3233\/JAD-2012-120640","article-title":"Novel disease-modifying therapies for Alzheimer\u2019s disease","volume":"31","author":"Jiang","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0480","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","article-title":"Role of RAGE in Alzheimer\u2019s Disease","volume":"36","author":"Cai","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2020.117996_bb0485","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14593","article-title":"Targeting amyloid clearance in Alzheimer\u2019s disease as a therapeutic strategy","author":"Nalivaeva","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117996_bb0490","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12640-015-9576-2","article-title":"Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease: from brain to periphery","volume":"29","author":"Yu","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0495","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00702-015-1431-3","article-title":"A prospective study on blood A\u03b2 levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer\u2019s disease","volume":"122","author":"Kitaguchi","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.lfs.2020.117996_bb0500","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-017-1721-y","article-title":"Peritoneal dialysis reduces amyloid-beta plasma levels in humans","author":"Jin","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.lfs.2020.117996_bb0505","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1039\/c3mt00161j","article-title":"The effect of Cu2+ and Zn2+ on the A\u03b242 peptide aggregation and cellular toxicity","volume":"5","author":"Sharma","year":"2013","journal-title":"Metallomics"},{"key":"10.1016\/j.lfs.2020.117996_bb0510","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1021\/jm100329q","article-title":"Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimers disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties","volume":"53","author":"Fern\u00e1ndez-Bachiller","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117996_bb0515","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1007\/s00018-012-1047-9","article-title":"Characterization of the role of metallothionein-3 in an animal model of Alzheimer\u2019s disease","volume":"69","author":"Manso","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.lfs.2020.117996_bb0520","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2020.117996_bb0525","first-page":"1","article-title":"Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer\u2019s rat model","volume":"7","author":"Guo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.117996_bb0530","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1021\/jm301079z","article-title":"Microtubule stabilizing agents as potential treatment for Alzheimers disease and related neurodegenerative tauopathies","volume":"55","author":"Ballatore","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117996_bb0535","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117996_bb0540","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1517\/14656566.2014.936848","article-title":"Latest treatment options for Alzheimer\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies","volume":"15","author":"Broadstock","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.lfs.2020.117996_bb0545","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.publhealth.23.100901.140525","article-title":"The public health impact of Alzheimer\u2019s disease, 2000\u20132050: potential implication of treatment advances","volume":"23","author":"Sloane","year":"2002","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.lfs.2020.117996_bb0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1079\/PNS2002146","article-title":"Antioxidant strategies for Alzheimer\u2019s disease","volume":"61","author":"Grundman","year":"2002","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.lfs.2020.117996_bb0555","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pbb.2015.02.012","article-title":"Non-selective NSAIDs improve the amyloid-\u03b2-mediated suppression of memory and synaptic plasticity","volume":"132","author":"Doost Mohammadpour","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2020.117996_bb0560","series-title":"Nonsteroidal Anti-inflammatory Drugs in Alzheimer\u2019s Disease","author":"Rich","year":"1995"},{"key":"10.1016\/j.lfs.2020.117996_bb0565","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2174\/1389200219666180813144834","article-title":"Probiotic supplementation in patients with Alzheimer\u2019s dementia - an explorative intervention study","volume":"15","author":"Leblhuber","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0570","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bpg.2015.12.001","article-title":"Probiotics: definition, scope and mechanisms of action","volume":"30","author":"Reid","year":"2016","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.lfs.2020.117996_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-13368-2","article-title":"Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer\u2019s disease","volume":"7","author":"Kobayashi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.117996_bb0580","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.arcmed.2012.09.008","article-title":"Physical activity, brain plasticity, and Alzheimer\u2019s disease","volume":"43","author":"Erickson","year":"2012","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0585","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/01.RES.0000250175.14861.77","article-title":"Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow","volume":"99","author":"Gertz","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0590","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3988\/jcn.2015.11.3.212","article-title":"Protective effects of physical exercise in Alzheimer\u2019s disease and Parkinson\u2019s disease: a narrative review","volume":"11","author":"Paillard","year":"2015","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.lfs.2020.117996_bb0595","first-page":"1","article-title":"Inhibitors of protein aggregates as novel drugs in neurodegenerative diseases","volume":"2","author":"Pietrobono","year":"2017","journal-title":"Glob. Drugs Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0600","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.117996_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401 - a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0610","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/joim.12166","article-title":"Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer\u2019s disease: the OmegAD study","volume":"275","author":"Freund Levi","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.lfs.2020.117996_bb0615","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2020.117996_bb0620","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0625","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2020.117996_bb0630","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40266-013-0108-6","article-title":"Successes and failures for drugs in late-stage development for Alzheimer\u2019s disease","volume":"30","author":"Berk","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.lfs.2020.117996_bb0635","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2020.117996_bb0640","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117996_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345791","article-title":"A review: treatment of Alzheimer\u2019s disease discovered in repurposed agents","volume":"35","author":"Appleby","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.lfs.2020.117996_bb0650","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(98)03086-4","article-title":"Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial","volume":"352","author":"Forette","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117996_bb0655","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JAD-2011-110347","article-title":"Associations of anti-hypertensive treatments with Alzheimer\u2019s disease, vascular dementia, and other dementias","volume":"26","author":"Davies","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2020.117996_bb0660","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5414\/CP201284","article-title":"Antihypertensive treatment and risk of dementia: a retrospective database study","volume":"50","author":"Wagner","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2020.117996_bb0665","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13543784.2017.1265504","article-title":"Pioglitazone for the treatment of Alzheimer\u2019s disease","volume":"26","author":"Galimberti","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2020.117996_bb0670","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31887\/DCNS.2009.11.2\/hhampel","article-title":"Biological markers for early detection and pharmacological treatment of Alzheimer\u2019s disease","volume":"11","author":"Hampel","year":"2009","journal-title":"Dialogues Clin. Neurosci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520307463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520307463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:21:00Z","timestamp":1735413660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520307463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":131,"alternative-id":["S0024320520307463"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117996","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117996"}}